Chart source: Finviz. Click opens TVTX quote page.
TVTX
Update: Jan 13, 2026 (PDUFA eve / after-hours volatility)
Travere Therapeutics – volatility update ahead of FILSPARI FSGS PDUFA
Super cautious note: what is confirmed vs what is still unknown. This is educational context, not a prediction.
Last close / after-hours (snapshot)
Regular close: $34.58 (Jan 12, 2026)
After-hours print (example feed): ~ $22.3 (very volatile)
After-hours volume (one feed): ~ 400.5K shares
Note: after-hours data can differ by venue/feed and can change quickly. Use your broker feed as the reference.
What the company officially said (confirmed)
PDUFA target date (FSGS sNDA): Jan 13, 2026
FDA information requests: company says FDA asked for more to characterize clinical benefit; responses submitted; currently under agency review
Preliminary commercial snapshot: FY25 U.S. net product sales ~ $410M; Q4 ~ $127M; year-end cash + marketable securities ~ $323M (preliminary)
Source is the company’s Jan 12, 2026 release and related SEC filing.
Merlintrader Health Score (1–5)
Preliminary: 2.9 / 5
Qualitative “robustness/fragility” snapshot for the next 12–18 months based on public info available today. Not a buy/sell signal.
Balance / runway (30%): supported by disclosed cash + ongoing product sales (preliminary numbers)
Catalyst concentration (30%): very high right now (binary FDA event)
Dilution / structure (20%): not fully assessed in this quick update; treat as “unknown risk”
Liquidity (10%): strong intraday liquidity, but AH liquidity can be thin and gap-prone
Execution & governance (10%): neutral in this note (no new governance facts asserted here)
Analyst Target Range (snapshot)
Low $31 | Avg ~$42.2 | High $49
Targets are a “photo” of analyst estimates, not a guarantee and not a recommendation. Range shown from consensus pages (snapshot Jan 12, 2026).
Focus
Today is about one thing: uncertainty around the FDA decision timing/outcome for the FILSPARI FSGS sNDA. The company explicitly highlighted FDA information requests right before the target date.
Warning
Maximum caution: after-hours moves can invalidate stops or create heavy slippage depending on broker/order settings and liquidity. Until an official FDA/company update is released, facts are limited.
Why moving
TVTX sold off sharply after-hours following a company update published right ahead of the FSGS PDUFA target date. The key line: the company said it recently received FDA information requests to further characterize clinical benefit, submitted responses, and those responses are under review.
What happened (confirmed vs unknown)
- Confirmed: company release + 8-K filed; PDUFA target date stated; FDA information requests disclosed; preliminary commercial/cash snapshot provided.
- Not confirmed (yet): there is no official FDA outcome in this note. No one outside FDA/company knows the final decision until it’s released.
- Market mechanism: after-hours liquidity is thinner, so moves can look “too big” vs the amount of actual shares traded.
Market view (cautious)
This is a classic binary-risk setup. The “information request” language increases uncertainty, but it is not, by itself, a final verdict. The only responsible stance right now is to treat the situation as high volatility / high headline risk until an official update lands.
What to watch next
- Official company press release / SEC filing if an FDA decision is received.
- FDA timing: decisions can come at various times; absence of news early does not confirm any outcome.
- Risk framing: gap behavior can persist into the open; do not assume “normal” price action immediately.
Perché si muove
TVTX ha avuto un crollo violento in after-hours dopo un update aziendale pubblicato a ridosso della data PDUFA (FSGS). La riga chiave: la società dice di aver ricevuto richieste di informazioni dalla FDA per “caratterizzare meglio il beneficio clinico”, di aver risposto, e che le risposte sono ora in review.
Cosa è successo (certo vs incerto)
- Certo: comunicato + 8-K depositato; PDUFA target date indicata; disclosure su richieste FDA; numeri preliminari su vendite/cassa.
- Non certo (ancora): in questa nota non esiste un esito ufficiale FDA. L’esito lo si conosce solo quando esce un aggiornamento ufficiale.
- Meccanica di mercato: in after-hours la liquidità è più sottile e i movimenti possono amplificarsi anche con volumi non enormi.
Vista di mercato (super cauta)
Questa è una situazione a rischio binario. La frase sulle “information requests” aumenta l’incertezza, ma da sola non è un verdetto. L’unica impostazione responsabile è trattare il tutto come alta volatilità / alto rischio headline fino a comunicazione ufficiale.
Cosa guardare adesso
- Press release / filing SEC se arriva la decisione FDA.
- Tempistiche: la decisione può uscire a orari diversi; il “silenzio” nelle prime ore non significa nulla.
- Gestione rischio: i gap e lo slippage possono continuare anche in apertura; non assumere subito un ritorno alla “normalità”.
Run-Up Strategy Focus (educational)
In biotech, the highest volatility often clusters around binary catalysts. A “run-up” approach (when appropriate) focuses on the pre-event window rather than the decision itself. This does not remove risk, but it can reduce exposure to the most extreme outcome swings.
Merlintrader RunUp Score (1–5)
Current setup: 2.2 / 5
Conservative rating given the proximity of the binary FDA event and the after-hours dislocation. This is not a recommendation.
Disclaimer
This note is for informational/educational purposes only and reflects a cautious interpretation of publicly available sources linked above. It is not investment advice, not a solicitation, and not a recommendation. Biotech events can be binary and extremely volatile; prices can gap and orders can experience slippage, especially outside regular hours. Always verify information with official releases/filings and use your own judgment.
